摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3H-咪唑并[1,5-a]吲哚 | 23136-62-1

中文名称
3H-咪唑并[1,5-a]吲哚
中文别名
——
英文名称
3H-Imidazo[1,5-a]indole
英文别名
1H-imidazo[1,5-a]indole
3H-咪唑并[1,5-a]吲哚化学式
CAS
23136-62-1
化学式
C10H8N2
mdl
——
分子量
156.18
InChiKey
BSZGFXNZRDBQDL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    17.3
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET/OU D'ISOXAZOLINE UTILISES COMME AGENTS ANTIBACTERIENS
    申请人:ASTRAZENECA AB
    公开号:WO2004048392A1
    公开(公告)日:2004-06-10
    A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I) wherein in (I) C is for example formula (D), formula (E), formula (H) wherein A and B are independently selected from (i) formula (J) and (ii) formula (K) m is 1 or 2; R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me; R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me; R1a is for example optionally substituted (1-10C)alkyl; R1b is for example selected from -NR5C(=W)R4, formula (a) , or formula (b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    公式(I)的化合物,或其药用可接受盐,或体内可解酯:公式(I)其中在(I)中,C例如为公式(D),公式(E),公式(H)其中A和B分别选自(i)公式(J)和(ii)公式(K)m为1或2;R2b和R6b,R2a和R6a,R3a和R5a,例如选自H,F,OMe和Me;R2b'和R6b',R2a'和R6a',R3a',R5a'例如选自H,OMe和Me;R1a例如为可选择地取代的(1-10C)烷基;R1b例如选自-NR5C(=W)R4,公式(a),或公式(b)其中HET-1例如为异恶唑基,HET-2例如为三唑基或四唑基。还描述了制备公式(I)的化合物的方法,含有它们的组合物以及它们作为抗菌剂的用途。
  • Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
    申请人:Syngenta Limited
    公开号:US20030144263A1
    公开(公告)日:2003-07-31
    Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    式(I)的化合物,或其药学上可接受的盐,或其体内可解的酯, 其中,例如,X为—O—或—S—; HET是一个可选择的取代的C-连接的含有2到4个异原子(独立选择自N、O和S)的5元杂芳环; Q从Q1和Q2中选择 R2和R3独立地为氢或; T从一系列基团中选择,例如,一个N-连接的(完全不饱和的)5元杂芳环系统或式(TC5)的基团: 其中Rc是,例如,R13CO—,R13SO2—或R13CS—; 其中R13是,例如,可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基;这些化合物可用作抗菌剂;并描述了其制备方法和含有它们的药物组合物。
  • [EN] OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTERIENS
    申请人:ASTRAZENECA AB
    公开号:WO2004056817A1
    公开(公告)日:2004-07-08
    A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: (I)wherein in (I) C is for example wherein A and B are independently selected from i) ii) and m is 1 or 2;R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me;R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me;R1a is for example optionally substituted (1-10C)alkyl;R1b is for example selected from NR5C(=W)R4, a) , or b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl.Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    公式(I)的化合物,或其药学上可接受的盐,或其中的体内解酯:(I)其中在(I)中,C例如,其中A和B分别选择自i)ii)和m为1或2;R2b和R6b,R2a和R6a,R3a和R5a,例如选择自H,F,OMe和Me;R2b'和R6b',R2a'和R6a',R3a',R5a'例如选择自H,OMe和Me;R1a例如是可选取代的(1-10C)烷基;R1b例如选择自NR5C(=W)R4,a),或b)其中HET-1例如为异噁唑基,HET-2例如为三唑基或四唑基。还描述了制备公式(I)的化合物的方法,含有它们的组合物以及它们作为抗菌剂的用途。
  • [EN] ANTIBACTERIAL OXAZOLIDINONES<br/>[FR] OXAZOLIDINONES ANTIBACTERIENS
    申请人:ASTRAZENECA AB
    公开号:WO2004056816A1
    公开(公告)日:2004-07-08
    A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I)wherein C is selected from D and E, formula (II) R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et;R2b and R6b are independently selected from for example H, F, CF3, Me and Et; R1b is -NRz-Z wherein Rz is for example hydrogen and Z is a 5- or 6-membered heteroaryl ring;R4 is for example an optionally substituted 5- or 6-membered heterocyclic ring system. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    一种具有以下结构式(I)的化合物,或其药学上可接受的盐,或其体内可解的酯:结构式(I)其中C从D和E中选择,结构式(II)R2a,R6a和R3a可独立选择,例如H,CF3,Me和Et;R2b和R6b可独立选择,例如H,F, ,Me和Et;R1b为-NRz-Z,其中Rz例如为氢,Z为5-或6-成员杂环芳基环;R4例如是一个可选择取代的5-或6-成员杂环基团。还描述了制备具有结构式(I)的化合物的方法,含有它们的组合物以及它们作为抗菌剂的用途。
  • Oxazolidinone derivatives with antibiotic activity
    申请人:——
    公开号:US20030216373A1
    公开(公告)日:2003-11-20
    Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC 5 ) 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内解酯,其中HET是一个N-连接的5-成员杂环芳基环,可选地在碳原子上被氧化或代氧基取代;和/或由1或2个(1-4C)烷基基团取代;和/或在一个可用的氮原子上由(1-4C)烷基基团取代;或者HET是一个N-连接的6-成员杂环芳基环,总共包含最多三个氮杂原子,可选地在碳原子上如上所述取代;Q是选自,例如,Q12R2和R3独立地是氢或;T是选自一系列基团,例如,如下式(TC5)3其中Rc是,例如,R13CO—,R13SO2—或R13CS—;其中R13是,例如,可选地取代的(1-10C)烷基或R14C(O)O(1-6C)烷基,其中R14是可选地取代的(1-10C)烷基;作为抗菌剂是有用的;并描述了它们的制备方法和含有它们的药物组合物。
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马鞭草(VERBENAOFFICINALIS)提取物 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛青二磺酸二钾盐 靛藍四磺酸 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红衍生物E804 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 靛噻 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛杂质3